Bioxytran Reports $2.07 Million Net Loss in Q1 2026, Faces Funding Challenges

Bioxytran, Inc. reported a net loss of $2.07 million for the first quarter of 2026, compared to a loss of $1.35 million during the same period in 2025. The company's total operating expenses surged to $1.93 million, significantly higher than the $515,142 recorded in the previous year. This increase was primarily driven by a substantial rise in general and administrative expenses, which included a $1.28 million stock-based compensation expense awarded to the CEO for his role in securing capital funding and establishing a distribution agreement. The loss per share remained consistent at $0.02 for both periods, with the weighted average number of shares outstanding increasing from 88.84 million to 112.28 million.

In terms of financial position, Bioxytran's total assets decreased to $615,253 as of March 31, 2026, down from $658,552 at the end of 2025. Current liabilities, however, rose sharply to $5.01 million from $3.25 million, reflecting increased accounts payable and accrued expenses, as well as a significant rise in un-issued shares liability. The company's accumulated deficit also widened to $23.11 million, compared to $21.04 million at the end of the previous fiscal year. The negative working capital increased to $4.55 million, raising concerns about the company's ability to continue as a going concern.

Strategically, Bioxytran is focused on advancing its clinical-stage pharmaceutical products, particularly in the fields of glycovirology and degenerative diseases. The company is developing BXT-25, an injectable anti-necrosis drug aimed at treating ischemic strokes, and has received approval for several investigational new drug (IND) applications in India and the U.S. for its ProLectin series targeting COVID-19. The company is also pursuing additional funding to support its ongoing research and development efforts, estimating a need for approximately $3.7 million to sustain operations over the next 15 months.

Operationally, Bioxytran has not yet generated revenue from its product lines, as it remains in the research and development phase. The company has reported a decrease in research and development expenses to $225,479 for the first quarter of 2026, down from $349,500 in the prior year, indicating a potential scaling back of R&D activities due to funding constraints. The company is actively seeking additional capital through private placements and other financing options to support its ongoing projects and operational needs.

Looking ahead, Bioxytran's management has expressed concerns regarding its liquidity and ability to fund operations without raising additional capital. The company is exploring various financing avenues but acknowledges the uncertainty surrounding the availability of funds on acceptable terms. The future of Bioxytran hinges on its ability to secure necessary funding to continue its development activities and navigate the challenges posed by its current financial situation.